Ontology engineering

© 2010 Nature America, Inc. All rights reserved.data page2009: Turning the cornerWalter YangDespite the shaky start to 2009, the biotech sector regained its financialfooting. Biotech indices were up, as were offerings and partnership monies.Excluding collaborations, the sector raised a total of $24.3 billion.Stock market performanceAlthough biotech indices were up ~16% last year, they underperformedother major indices.Index1,5001,4001,3001,2001,1001,00090080070012/081/09Swiss MarketNASDAQ BiotechNASDAQ2/093/094/095/09S&P 500Dow JonesBioCentury 1006/09Month endingGlobal biotech venture capital (VC) investmentVenture money fell slightly last year, as private companies raised$5.1 billion versus $5.3 billion in 2008.VC amount raised ($ millions)1078,000 1,436Asia-Pacific7,00069 78 58 5,24155Europe1,213 1,451 1,206531,1456,00040 4,045 3,871 4,3151,1304,070 3,947 Americas5,000 7973,1514,0003,0002,0001,00002003AmericasEuropeAsia-Pacific7/098/092004 2005 2006 2007 2008Year2003 2004 2005 2006 2007 2008 2009184775190826182959204818223105921210161968749/092009Table indicates number of VC investments and includes rounds where the amountraised was not disclosed. Source: BCIQ: BioCentury Online IntelligenceNotable 2009 dealsIPOsPercentCompany (lead underwriters)Amountraised($ millions)change instock pricesince offerDatecompletedTalecris (Morgan Stanley, Goldman Sachs, Citigroup, $550.0 17% 30-SepJPMorgan)Movetis (Credit Suisse, KBC) $146.0 3% 3-DecCumberland (UBS, Jefferies, Wells Fargo) $85.0 –5% 10-AugOmeros (Deutsche Bank) $68.2 –30% 7-OctChina Nuokang (Jefferies) $40.7 –13% 9-DecVenture capitalAmountCompany (lead investors)raised($ millions)Roundnumber Date closedClovis Oncology a (Domain, New Enterprise Associates, $145.0 NA 21-MayVersant, Aberdare, Abingworth, Frazier, ProQuest,company management)Zogenix (Clarus, Domain) $71.0 2 07-DecBioVex (Forbion, Morningside, Ventech, MVM) $70.0 6 10-NovPacific Biosciences b (Deerfield, Intel) $68.0 5 12-AugHyperion (Bay City Capital, Panorama Capital) $60.0 3 30-JunNovImmune (BZ Bank) $56.4 NA 12-MaySopherion (Zoticon Bioventures) $55.0 3 18-Feba Lead investor not available. b Series E extension.10/0911/0912/09Although initial public offerings showed signs of resuscitation (at least13 more companies are now in the queue), follow-on financings came inabove $6 billion—the second-best year over the past decade.Global biotech industry financingThe boost in partnership promises to US biotechs and follow-on financingspushed industry funding to $61.3 billion, up 82% from 2008.Year20092008200720062005200420.0 3.2 5.3 3.1 1.9 0.117.3 6.1 5.4 2.7 4.8 1.910.9 8.8 5.3 2.9 3.3 2.620038.9 9.1 4.0 2.2 3.9 0.50 10 20 30 40 50 60 70Amount raised ($ billions)36.9 10.0 5.1 2.2 6.0 0.922.4 11.7 6.8 4.7 4.4 3.019.8 11.9 5.6 4.7 5.6 2.0PartneringDebt and otherVenture capitalPIPEsFollow-onsIPOsPartnership figures are for deals involving a US company. Source: BCIQ: BioCenturyOnline Intelligence, Burrill & Co.PIPEs, private investments in public equity; IPOs, initial public offeringsGlobal biotech initial public offerings (IPOs)The North American IPO market showed signs of life, with four companiesraising $705 million versus only one raising $6 million in 2008.Amount raised ($ millions)5853,5001,055 Asia-Pacific2301,3093,000474Europe1,852982,50015 869930Americas1,0632,0009131,5001,000500043194832003AmericasEuropeAsia-Pacific1211562004 2005 2006 2007 2008Year2003 2004 2005 2006 2007 2008 200981535126182432621323217132433651587052009Table indicates number of IPOs. Source: BCIQ: BioCentury Online IntelligenceMergers and acquisitionsTarget Acquirer Value ($ millions) Date announcedGenentech Roche $46,800 12-MarSepracor Dainippon Sumitomo $2,600 3-SepMedarex Bristol-Myers Squibb $2,400 22-JulCV Therapeutics Gilead Sciences $1,400 12-MarCougar Biotechnology Johnson & Johnson $1,000 21-MayOvation Pharmaceuticals H. Lundbeck $900 09-FebProteolix Onyx Pharmaceuticals $851 12-OctLicensing /collaborationResearcher InvestorValue($ millions) Deal descriptionPTCTherapeuticsRoche $1,924 Develop small molecules against four central nervoussystem disease targetsNektar AstraZeneca $1,505 Worldwide rights to NKTR-118 for opioid-induced constipationand NKTR-119 for pain without constipationIncyte Novartis $1,310 Ex-US rights to INCB18424; in phase 3 for myelofibrosis;worldwide rights to preclinical INCB28060Targacept AstraZeneca $1,240 Worldwide rights to develop and commercialize majordepressive disorder compound TC-5214Exelixis Sanofiaventis>$1,161 Exclusive, worldwide rights to XL147 and XL765 inphase 1b/2 to treat cancerZymoGenetics Bristol-MyersSquibb$1,105 Codevelop and commercialize ZymoGenetics’ phase 1hepatitis C virus compound PEG-interferon lambdaAmylin Takeda >$1,075 Codevelop and commercialize therapeutics for obesityand related indicationsAlder Bristol-MyersSquibb$1,069 Worldwide rights to ALD518 for all indications, exceptcancer116 volume 28 number 2 february 2010 nature biotechnology